2760. Accounting for Vaccination History in Estimates of Current Season Vaccine Effectiveness in the US Flu VE Network, 2012–2013 Through 2017–2018
Sara S. Kim, MPH1; Ivo Foppa, ScD2; Jessie R. Chung, MPH1; Edward Belongia, MD3; Huong McLean, PhD, MPH1; Arnold Monto, MD4; Joshua G. Petrie, PhD, MPH1; Richard Zimmerman, MD, PhD1; Mary Patricia Nowalk, PhD5; Natasha B. Murthy, MBBS1; Kemppapura Murthy, MBBS, MPH1; Michael L. Jackson, PhD, MPH1; Brendan Flannery, PhD1; Manish Patel, MD1; ORISE, US Centers for Disease Control and Prevention, Atlanta, Georgia; 2Battelle; Centers for Disease Control and Prevention, Atlanta, Georgia; 3Marshfield Clinic Research Institute, Marshfield, Wisconsin; 4University of Michigan School of Public Health, Ann Arbor, Michigan; 5University of Michigan, Ann Arbor, Michigan; 6University of Pittsburgh Schools of Health Sciences, Texas A&M University, College Station, Texas; 7Baylor Scott & White Health; Texas A&M University HSC COM, Temple, Texas; 8Kaiser Permanente Washington Health Research Institute, Seattle, Washington; 9US Centers for Disease Control and Prevention, Atlanta, Georgia
Session: 278. Vaccines: Influenza Saturday, October 5, 2019: 12:15 PM

Background: Current season vaccine effectiveness (VE) and influenza risk may vary in persons based on vaccination history. United States Influenza Vaccine Effectiveness (US Flu VE) Network studies have explored prior vaccination effects using a single referent group of patients unvaccinated in both the prior and current seasons. We investigated vaccine benefit among those with and without prior season vaccination.

Methods: Our analysis included data from the US Flu VE Network among patients aged ≥29 years old with acute respiratory illness during 6 influenza seasons, 2012–2013 through 2017–2018. We determined current and prior season vaccination status from documented immunizations. Current season VE against laboratory confirmed influenza was estimated using multivariate logistic regression with an interaction term for prior season vaccination. Models were adjusted for age, calendar time, high-risk status, and site.

Results: Of 31,819 patients included in the analysis over 6 seasons, 9,188 were influenza positive by RT–PCR. Percent flu positivity was greatest among those unvaccinated (34%), followed by those vaccinated in the prior season only (29%), those vaccinated in both seasons (25%), and those vaccinated in the current season only (23%). Among patients with prior season vaccination, current season VE against any influenza was 14% (95% Cl: 5, 22) and against A(H3N2), A(H1N1)pdm09, and B, respectively. 10% (95% Cl: 3, 16), 13% (95% Cl: 7, 20), and 6% (95% Cl: 3, 10), respectively. Among patients unvaccinated in the prior season, VE was 42% (95% Cl: 37, 47) against any influenza in the current season and was 31% (95% Cl: 22, 39), 57% (95% Cl: 47, 65), and 55% (95% Cl: 48, 61) against A(H3N2), A(H1N1)pdm09, and B, respectively. We observed significant interaction of prior season vaccination on current season VE in 4 of 6 seasons (P < 0.20).

Conclusion: Current season vaccination was overall protective regardless of vaccination history. Among those vaccinated in the prior season, current season vaccination may provide some benefit in addition to residual protection from previous vaccination.

Disclosures. All authors: No reported disclosures.

2761. Interventions to Improve Influenza Vaccination Coverage in Children with Medical Comorbidities: A Meta-Analysis
Daniel Norman, MPH1; Rosanne Barnes, PhD2; Margie Danchin, MBBS, PhD, FRACP3; Holly Salee, BSc, MPH, PhD2; Hanah C. Moore, PhD2; Christopher C. Blyth, MBBS(Hons), DCH, FRACP, FRCPA, PhD2; 1Telethon Kids Institute, Nedlands, Western Australia, Australia; 2Telethon Kids Institute, The University of Western Australia, Nedlands, Western Australia, Australia; Murdoch Children’s Research Institute, Parkville, Victoria, Australia; 3University of Western Australia, Randwick, New South Wales, Australia; 4Perth Children’s Hospital, Nedlands, Western Australia, Australia
Session: 278. Vaccines: Influenza Saturday, October 5, 2019: 12:15 PM

Background: Influenza vaccination is the most effective influenza prevention tool for children with medical comorbidities. Despite this, coverage remains inadequate. Numerous interventions to improve vaccination coverage have been assessed, yet there remains a paucity of data comparing the relative efficacy and effectiveness of different interventions.

Methods: We searched MEDLINE, PubMed, Scopus, Embase, CINAHL, CENTRAL, and Web of Science (1980 to March 2019) for studies evaluating interventions which sought to improve influenza vaccine coverage in children with medical comorbidities. Interventions were divided into those targeting parents, targeting vaccination providers, and targeting the hospital, clinic or ward. Screening and data extraction from publications meeting inclusion criteria was performed by two reviewers. Results were pooled and meta-analyses were performed using Mantel–Haenszel random-effects models in Review Manager 5.

Results: 35 articles met inclusion criteria; 14 cross-sectional, 12 randomized trials, and 9 cohort studies, 25 articles had sufficient data for pooled analysis. Of the included interventions, 17 were based within primary care or community settings, 17 were based in hospitals or tertiary clinics, and 1 intervention was conducted across both primary and tertiary settings. Interventions overall increased influenza vaccination likelihood by 33% (RR = 1.33; 95% CI 1.31, 1.35). Interventions targeting providers’ influenza vaccine knowledge increased vaccine coverage (RR = 1.42; 95% CI
1.36, 1.49) greater than those targeting parental knowledge (RR = 1.23; 95% CI 1.21, 1.26). Conversely, vaccination reminders targeting parents increased vaccine coverage (RR = 1.53; 95% CI 1.49, 1.58) greater than reminders targeting providers (RR = 1.23; 95% CI 1.20, 1.27). Interventions targeting hospitals, clinics or ward processes had the weakest impact on coverage (RR = 1.15; 95% CI 1.13, 1.17).

Conclusion: Interventions targeting parents, providers, and places individually have all shown to improve influenza vaccination in children with medical comorbidities. However, specifically targeting providers’ vaccine knowledge and parental reminders appear to have the greatest impact on vaccine uptake.

Disclosures. All authors: No reported disclosures.

2762. A Cohort Analysis of Completion of the Pediatric Measles-Mumps-Rubella-Varicella Series in the United States
Lara J. Wolfson, PhD; Masuku K. Nyaku, DrPh; Shilka Surati, MPH; Zhiwen Liu, PhD; Manjiri D. Pawaskar, PhD; Merck & Co., Inc., Kenilworth, New Jersey

Session: 279. Vaccines: Viral Non Influenza
Saturday, October 5, 2019: 12:15 PM

Background: Since 2006, the recommended US vaccination schedule has included combination Measles-Mumps-Rubella (MMR) vaccine and separate Varicella (V) vaccine administered as first dose between 12–15 months, and second dose between 4–6 years, administered either separately or as a combination MMRV vaccine. Vaccine coverage alone does not provide information on the timeliness of vaccine receipt, a critical step in ensuring optimal protection, thus, we sought to evaluate overall series completion rates and identify factors related to under-vaccination.

Methods: A cohort of children born between 2006 and 2010, with continuous enrollment from birth to age 7 in the MarketScan® Commercial Claims and Encounters Database was studied. The administration of first and second doses of MMR- and V-containing vaccines was evaluated. Administration timeliness was categorized as recommended, acceptably early (prior to age 4 for the second dose), late (after the recommended time period), invalid, or missing at least one vaccine. A logistic regression analysis evaluated factors associated with under-vaccination.

Results: Among the 104,999 children included, 55.9% were vaccinated within the recommended time periods for both first and second doses, with timeliness higher for the second dose (80.1%) than the first dose (63.5%). By age 4, 20.1% of children were missing the first dose of either MMR or V (or both) and by age 7, 26.6% of children were missing at least one dose, with 9.4% missing all required vaccines. Factors associated with missing or delayed vaccination included geographic region, vaccination by a provider other than a pediatrician, and, for the second dose, having missed or delayed the first dose of either MMR or V (or both) and by age 7, 26.6% of children were missing at least one dose, with 9.4% missing all required vaccines. Factors associated with missing or delayed vaccination included geographic region, vaccination by a provider other than a pediatrician, and, for the second dose, having missed or delayed the first dose. Having additional children in the family was associated with a higher likelihood of missed or delayed vaccination for the first dose, but with a lower likelihood of missed or delayed vaccination for the second dose.

Conclusion: About one in four children were missing at least one dose of MMR or V by age 7, indicating vaccine coverage is below Healthy People 2020 95% target. Additionally, delays in administration of the first dose indicate a potential for the development of cohorts of susceptible children large enough to sustain outbreaks. Strategies for addressing timeliness of vaccine receipt should incorporate factors associated with under-vaccination.

Disclosures. All authors: No reported disclosures.

2763. Uptake and Safety of Measles-Mumps-Rubella (MMR) Vaccine in Adolescents and Adults in the Vaccine Safety Datalink
Kaya E. Hanson, MPH; Huong McLean, PhD, MPH; Mona Marin, MD; Lakshmi Panagiotakopoulou, MD, MPH; Eric Weintrub, MPH; Matthew F. Daley, MD; Holly Groom, MPH; Lisa Jackson, MD, MPH; Steven J. Jacobsen, MD, PhD; Nicola Klein, MD, PhD; James D. Nordin, MD, MPH; Edward Belongia, MD; Marshall Clinic Research Institute, Marshfield, Wisconsin; Centers for Disease Control and Prevention, Atlanta, Georgia; Kaiser Permanente Colorado, Aurora, Colorado; Kaiser Permanente Northwest, Portland, Oregon; Kaiser Permanente Washington Health Research Institute, Seattle, Washington; Kaiser Permanente Southern California, Pasadena, California; Kaiser Permanente Northern California, Oakland, California; HealthPartners Institute, Minneapolis, Minnesota

Session: 279. Vaccines: Viral Non Influenza
Saturday, October 5, 2019: 12:15 PM

Background: MMR vaccine is given routinely to young children but may be given at other ages. We described MMR use in adolescent and adult populations in the Vaccine Safety Datalink (VSD) and estimated the incidence of medically-attended outcomes after MMR to inform future studies estimating vaccine-associated risk.

Methods: The study population included adolescents (9–17 years) and adults (≥18 years) in VSD who received at least one MMR vaccine from 2010 through 2016. Outcomes were pre-specified based on previous vaccine safety studies and categorized as clinically serious (anaphylaxis, encephalitis/myelitis, GBS, meningitis, seizure) or non-serious (allergic reaction, arthropathy, fever, injection site reaction, lymphadenopathy, non-specific reaction, parotitis, rash, syncope). Outcomes were identified by searching for ICD-9 and ICD-10 diagnosis codes in post-vaccination exposure windows. Medical records were reviewed for all serious outcomes to verify incident diagnoses. Incidence and 95% confidence intervals were calculated for validated serious outcomes.

Results: 146,503 adolescents and adults received 162,992 MMR vaccines during the study period. The mean age at vaccination was 33.7 years, 65% were female, and 53% received at least one other vaccine simultaneously. Demographic and vaccination characteristics varied across age groups (Table 1). The analysis of post-vaccination outcomes included 162,053 MMR vaccinations. The incidence of validated serious outcomes was low, ranging from 0 to 6.8 per 100,000 vaccinations. Only one serious outcome (anaphylaxis) was noted to be vaccine-associated in the medical record. Incidence of clinically non-serious outcomes varied from 0.4 to 56.0 per 10,000 vaccinations. Injection site reactions were more common among adolescents (118.1 per 10,000 vaccinations), who also had a higher frequency of simultaneous vaccination (80%).

Conclusion: Clinically serious outcomes were rare following MMR vaccination. Rates of clinically non-serious outcomes varied but were similar to or lower than previous reports in children. This descriptive analysis did not evaluate the association between MMR and adverse events. Future analysis with an appropriate comparison group is needed for risk estimation.

Disclosures. All authors: No reported disclosures.